8-K: EyePoint's DURAVYU Trial Shows Mixed Results in Wet AMD

EyePoint, Inc. announced updated results from its LUGANO Phase 3 clinical trial for DURAVYU in wet AMD, revealing a favorable safety profile and reduced treatment burden but failing to meet the primary non-inferiority endpoint.

Summary

• EyePoint, Inc. has released updated results from its LUGANO Phase 3 clinical trial for DURAVYU in wet age-related macular degeneration (AMD).
• The trial did not achieve statistical non-inferiority in the full dataset for the primary endpoint, although it was non-inferior when excluding an asymmetric cohort.
• DURAVYU demonstrated a significant reduction in treatment burden, with 42% fewer injections on average compared to aflibercept, and achieved superiority in this metric.
• Supplement-free rates were high, with 79% of DURAVYU patients receiving zero or one supplement up to Week 56.
• The drug exhibited a favorable safety profile with repeat dosing, with no cases of severe intraocular inflammation or other serious adverse events.
• Geographic atrophy (GA) onset and progression rates were similar or lower in the DURAVYU arm compared to aflibercept and historical averages.
• The company plans to submit a New Drug Application (NDA) for DURAVYU in the first half of 2027, contingent on positive results from the LUCIA trial.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed result. While DURAVYU shows promise in reducing treatment burden and has a favorable safety profile, it failed to meet the primary endpoint for non-inferiority in the LUGANO trial, which is a significant setback.

Positives

• DURAVYU demonstrated a significant reduction in treatment burden, achieving superiority over on-label aflibercept with 42% fewer injections on average.
• High supplement-free rates were observed, with 79% of patients receiving zero or one supplement up to Week 56.
• The drug maintained a favorable safety profile with repeat dosing, with no cases of severe intraocular inflammation, retinal vasculitis, or endophthalmitis.
• Geographic atrophy (GA) onset and progression rates were similar or lower in the DURAVYU arm compared to aflibercept and historical averages.
• Anatomic control was strong, with over 50% of eyes controlled by DURAVYU alone up to Week 56.
• Excluding an asymmetric cohort, DURAVYU demonstrated non-inferiority in mean change in BCVA from baseline, with a nominal non-inferiority p-value of 0.0096.
• Median analysis also demonstrated non-inferiority in BCVA change from baseline.

Negatives

• DURAVYU did not achieve statistical non-inferiority in the full LUGANO dataset for the primary endpoint.
• An asymmetric cohort of 9 patients (4%) in the DURAVYU arm experienced vision loss (>= 15 letters) due to non-wet AMD etiologies, which drove the primary endpoint result.
• The control arm (aflibercept) had a significantly lower rate of 15-letter vision loss (0.5%) compared to prior wet AMD trials.

Risks

• Uncertainties and delays relating to communications with the U.S. Food and Drug Administration and the ability to obtain regulatory approval for DURAVYU.
• The risk that results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis.
• Unexpected safety or efficacy data observed during clinical trials.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Delays, interruptions or failures in the manufacture and supply of product candidates.
• Uncertainties regarding the FDA warning letter pertaining to the company's manufacturing facility.

Future Outlook

EyePoint plans to submit a New Drug Application (NDA) for DURAVYU for wet AMD in the first half of 2027, contingent on positive results from the LUCIA trial. Topline data for the DME trials (COMO and CAPRI) are expected in Q4 2027. The company anticipates a pre-NDA meeting with the FDA in Q4 2026.

Management Comments

• Confidence in DURAVYU as a potential treatment for wet AMD.
• Belief that DURAVYU is well positioned to be a potentially practice-changing product and potentially the first-to-market among all investigational sustained release treatments for the two largest retinal disease markets, wet AMD and DME.
• Belief that DURAVYU is the only TKI in development for DME.
• Belief that DURAVYU's potential real-world application in multiple retinal disease indications and established trial designs position DURAVYU for clinical and commercial success.
• Belief that DURAVYU brings a potential new multi-mechanism of action and treatment paradigm for retinal diseases beyond existing anti-VEGF large molecule ligand blocking therapies.

Industry Context

StockSavvy.ai notes that the sustained-release drug delivery market for retinal diseases is highly competitive, with companies like Regeneron (Eylea) and Roche (Vabysmo) holding significant market share. EyePoint's DURAVYU aims to differentiate itself with a longer duration of action and a multi-mechanism of action, potentially reducing treatment burden for patients. However, the failure to meet the primary endpoint in LUGANO raises questions about its efficacy compared to existing standard of care.

Comparison to Industry Standards

• The LUGANO trial followed a non-inferiority pathway similar to five most recent FDA approvals in wet AMD.
• The aflibercept control arm in LUGANO showed a significantly lower rate of 15-letter vision loss (0.5%) compared to historical data from other wet AMD trials, such as VIEW 1/2 (4.4-4.9%), HAWK/HARRIER (4.8-5.5%), TENAYA/LUCERNE (2.7-5.9%), PULSAR (3.3%), and DAVIO (7.7%). This overperformance of the control arm may have impacted the non-inferiority assessment.
• The geographic atrophy (GA) growth rate in the LUGANO trial was reported as slower than the historical published average of ~2.0 mm2/year.
• The safety profile of DURAVYU with repeat dosing is being compared to the established safety profiles of existing anti-VEGF therapies.

Stakeholder Impact

• Shareholders may be concerned by the failure to meet the primary endpoint in the LUGANO trial, potentially impacting future stock performance.
• Patients with wet AMD may be disappointed by the setback in the development of a potentially new treatment option, although the reduced treatment burden and favorable safety profile remain positive aspects.
• Physicians may be hesitant to adopt DURAVYU if regulatory approval is delayed or if further efficacy concerns arise, despite the potential benefits in treatment burden reduction.

Next Steps

• Report topline data from the Phase 3 LUCIA wet AMD trial.
• Engage FDA to discuss Wet AMD data package.
• Submit comprehensive Phase 3 data package (LUGANO & LUCIA) to FDA.
• Report topline data simultaneously for both pivotal DME trials, COMO and CAPRI.

Key Dates

Recommendation

The mixed results from the LUGANO trial, particularly the failure to meet the primary non-inferiority endpoint, warrant a cautious approach. While DURAVYU shows promise in reducing treatment burden and has a favorable safety profile, the primary efficacy miss is a significant concern. The upcoming LUCIA trial results will be critical. A 'hold' recommendation reflects the uncertainty and the need for further data before considering a more definitive investment stance.

Keywords

DURAVYU, wet AMD, retinal disease, clinical trial, Phase 3, non-inferiority, treatment burden, sustained release